Brain and CNS (12/12) | 2WWR: 0–100% (8 audits)* | – | 23–100% (4 audits)* | – | – | 22% (1 audit) |
Breast (59/72) | 2WWR: 65–99% (20 audits) | Cancer: 0% (1 audit)* | 18–96% (9 audits) | 78% (1 audit) | 15–45% (2 audits) | 5–17% (2 audits) |
Children (9/9) | 2WWR: 91–100% (4 audits)* | – | 60–100% (4 audits)* | – | – | – |
Lower GI (47/71) | 2WWR: 53–100% (26 audits)* | Cancer: 29% (1 audit)* | 52–74% (6 audits) | 33–87% (3 audits) | 9–19% (2 audits) | 0% (1 audit) |
Upper GI (36/54) | 2WWR: 76–100% (14 audits)* | Cancer: 100% (1 audit)* | 67–96% (5 audits) | 59–98% (2 audits) | 5–36% (2 audits) | 2% (1 audit) |
Gynaecological (36/45) | 2WWR: 42–100% (19 audits)* | Cancer: 75% (1 audit)* | 64–94% (6 audits) | 82% (1 audit) | 0–25% (2 audits)* | 11% (1 audit) |
Haematological (21/26) | 2WWR: 0–100% (10 audits)* | – | 75–100% (5 audits)* | 100% (1 audit)* | – | 0–26% (2 audits)* |
Head and neck (23/30) | 2WWR: 0–86% (12 audits)* | Referrals: 35% (1 audit) Cancer: 100% (1 audit)* | 36–76% (6 audits) | 85% (1 audit) | 40–43% (2 audits)* | 10% (1 audit) |
Lung (33/43) | 2WWR: 78–100% (15 audits) | – | 87–97% (5 audits) | 95% (1 audit) | 0–5% (2 audits)* | 6% (1 audit) |
Sarcomas (10/11) | 2WWR: 60–100% (6 audits)* | Cancer: 100% (1 audit)* | 67–100% (4 audits)* | – | – | – |
Skin (43/59) | 2WWR: 9–97% (20 audits)* | – | 13–84% (6 audits) | – | 1–42% (2 audits) | 3% (1 audit) |
Urological (34/43) | 2WWR: 50–100% (15 audits)* Cancer: 94% (1 audit) | Referrals: 94% (1 audit) Cancer: 48% (1 audit) | 78–91% (4 audits) | 86% (1 audit) | 17% (1 audit)* | – |